Noom Eyes Glp-1s For Longevity, Not Just Weight Loss

The digital health platform’s new GLP-1 Rx program pairs microdosed weight-loss drugs with biomarker testing and behavior change to target early metabolic risk

For consumers intrigued by the promise of GLP-1 medications but who don’t meet the BMI requirements typically tied to prescriptions, the door has largely stayed closed — until now.

Digital health platform Noom has launched Proactive Health Microdose GLP-1 Rx, a $149-per-month preventive health program that combines low-dose GLP-1 medication and at-home biomarker testing with its behavioral coaching platform.

Rather than focusing solely on weight loss, the program is meant to address early metabolic risk factors linked to chronic disease and support longevity, and is open to individuals with a BMI of 21 or higher.

Noom’s latest program ships personalized microdoses of GLP-1 medication directly to members, with blood testing every four months that tracks 17 biomarkers tied to metabolic, cardiovascular and hormonal health. The data is delivered through the Noom app alongside the platform’s habit-building tools.

“Today marks the start of a new era for Noom,” Noom CEO Geoff Cook said. “Now, we can intervene sooner. We can get in front of chronic disease and reach people before metabolic disorder takes root. GLP-1s were recently declared ‘proven longevity medicine’ from the keynote stage at a major pharmaceutical industry conference in Copenhagen, which was chronicled in the journal Nature last month.”

Dr. Jeffrey Egler, Noom’s chief medical officer, noted that roughly three in four adults in midlife years are living with at least one chronic health condition.

“The problem we’re solving is that most Americans are living with suboptimal health — and their blood biomarkers show it,” said Dr. Egler. “That eventually manifests as chronic disease.”

GLP-1 Use Is Booming in America

GLP-1 adoption is accelerating quickly across the U.S.

New Gallup data shows that 12.4% of American adults now report using drugs like Ozempic and Wegovy for weight loss, more than double the share from early 2024 and driven largely by middle-aged adults. At the same time, public sentiment toward GLP-1 is changing.

Recent data from telehealth provider Ro shows that familiarity plays a major role in acceptance, as people who know someone on a GLP-1 are significantly more likely to view the drugs favorably.

In longevity circles, experts such as Dr. Frank Lipman and Dr. Tyna Moore have pointed to GLP-1s as a potentially meaningful tool for metabolic health and healthy aging, particularly when used strategically and at lower doses.

Noom’s latest launch also comes as UBS has identified longevity as one of the most powerful investment themes of the next decade, projecting the global “longevity economy,” spanning health tech, biotech, wellness and preventive care, could reach $8 trillion by 2030.

The post Noom Eyes GLP-1s for Longevity, Not Just Weight Loss appeared first on Athletech News.